October 28, 2009 External Link
Focus Therapeutics successfully organized a partnership ceremony between the state of New Jersey and Daegu Metropolitan, Korea at Rutgers University, USA.
September 15, 2009
Focus Therapeutics made an agreement to become an exclusive representative for drug sourcing in S. Korea for Domain associates, LLC.
Focus Therapeutics organized an international business forum with Daegu-Gyungbook Institute at Interbulgo Hotel in Daegu, Korea. This forum specifically handled the issues of how to successfully develop a bio-medical cluster in Daegu, Korea. The Korean government has selected Daegu as a place for the Hightech Medical Complex, and this nationwide project will be launched in the fall of 2012.
March 5 2010
The graduate program for technology innovation and management (www. postechtim.ac.kr) at Postech (list state or region, country) and the master of science and business program at Rutgers (www. psm.rutges.edu) will launch a dual degree program in 2011 under the support of Focus.
August 18, 2010
Focus Therapeutics made an agreement to launch a healthcare dedicated venture capital firm in S. Korea.
October 11, 2010
Focus Therapeutics initiated an MOU between Korea University and Rutgers, the State University of New Jersey.
January 15 2011
Focus Therapeutics and Propharma Partners established S. Korean licensing initiative to introduce late stage and therapeutic marketed products to S. Korean Market.
March 15 2011
Focus and Shire, a global specialty biopharma entered into an agreement that Focus to be an exclusive consultant for drug candidate in-licensing from S. Korea.
September 1 2012
Focus made a consulting agreement with CHA Bio and Diostech, S. Korea to source phramaceuticals, biotechnology and device.
June 27 2013
Focus facilitated the partnership agreement between CHA Bio and Diostech, S. Korea and Pluristem, Israel.
August 6 2013
Focus facilitated the partnership agreement between CHA Bio and Diostech, S. Korea and Wake Forest Innovations, US.
September 1 2013
Focus made an exclusive consulting agreement with Melior Doscovery, US to license-out MLR-1023, a first-in-class insulin sensitizer for the treatment of TII diabetes.
December 3 2014
Focus facilitated the partnership agreement between Melior Discovery, US and Bukwang Pharma, Korea.